114 related articles for article (PubMed ID: 27053500)
61. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
62. Cigarette Smoking and Prostate Cancer Mortality in Four US States, 1999-2010.
Jones MR; Joshu CE; Kanarek N; Navas-Acien A; Richardson KA; Platz EA
Prev Chronic Dis; 2016 Apr; 13():E51. PubMed ID: 27079649
[TBL] [Abstract][Full Text] [Related]
63. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer?
Delongchamps NB; Portalez D; Bruguière E; Rouvière O; Malavaud B; Mozer P; Fiard G; Cornud F;
J Urol; 2016 Oct; 196(4):1069-75. PubMed ID: 27079582
[TBL] [Abstract][Full Text] [Related]
64. Metformin Has a Positive Therapeutic Effect on Prostate Cancer in Patients With Type 2 Diabetes Mellitus.
Chong RW; Vasudevan V; Zuber J; Solomon SS
Am J Med Sci; 2016 Apr; 351(4):416-9. PubMed ID: 27079349
[TBL] [Abstract][Full Text] [Related]
65. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Urology; 2016 Jul; 93():68-76. PubMed ID: 27079130
[TBL] [Abstract][Full Text] [Related]
66. Predictors of pathological upgrading in low-risk prostate cancer patients without hypointense lesions on an apparent diffusion coefficient map of multiparametric magnetic resonance imaging.
Kang M; Song B; Lee I; Lee SE; Byun SS; Hong SK
World J Urol; 2016 Nov; 34(11):1541-1546. PubMed ID: 27074937
[TBL] [Abstract][Full Text] [Related]
67. ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer.
Lu LI; Zhang H; Pang J; Hou GL; Lu MH; Gao X
Oncol Lett; 2016 Apr; 11(4):2532-2538. PubMed ID: 27073512
[TBL] [Abstract][Full Text] [Related]
68. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
[TBL] [Abstract][Full Text] [Related]
69. Results of tadalafil treatment in patients following an open nerve-sparing radical prostatectomy.
Hirik E; Bozkurt A; Karabakan M; Onuk Ö; Balcı MB; Aydın M; Çakan M; Nuhoglu B
Arch Ital Urol Androl; 2016 Mar; 88(1):4-6. PubMed ID: 27072168
[TBL] [Abstract][Full Text] [Related]
70. Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review.
Rahal AK; Badgett RG; Hoffman RM
PLoS One; 2016; 11(4):e0153417. PubMed ID: 27070904
[TBL] [Abstract][Full Text] [Related]
71. Predicting toxicity in radiotherapy for prostate cancer.
Landoni V; Fiorino C; Cozzarini C; Sanguineti G; Valdagni R; Rancati T
Phys Med; 2016 Mar; 32(3):521-32. PubMed ID: 27068274
[TBL] [Abstract][Full Text] [Related]
72. Prostate MRI based on PI-RADS version 2: how we review and report.
Steiger P; Thoeny HC
Cancer Imaging; 2016 Apr; 16():9. PubMed ID: 27067275
[TBL] [Abstract][Full Text] [Related]
73. Prostate cancer radiation therapy: A physician's perspective.
Dal Pra A; Souhami L
Phys Med; 2016 Mar; 32(3):438-45. PubMed ID: 27056435
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of tolerance and toxicity of high-dose-rate brachytherapy boost combined with interstitial hyperthermia for prostate cancer.
Kukiełka AM; Hetnał M; Bereza K
Int J Hyperthermia; 2016 May; 32(3):324-30. PubMed ID: 27056204
[TBL] [Abstract][Full Text] [Related]
75. Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer.
Acosta-Vega NL; Varela R; Mesa JA; Garai J; Baddoo MC; Gómez-Gutiérrez A; Serrano-Gómez SJ; Lemus MN; Serrano ML; Zabaleta J; Combita AL; Sanabria-Salas MC
Cancer Med; 2023 Feb; 12(4):4306-4320. PubMed ID: 36329628
[TBL] [Abstract][Full Text] [Related]
76. Candesartan induces tumor vascular normalization to improve the efficacy of radiotherapy in the therapeutic window.
Zhu F; Yao W; Huang Y; Chen Y; Wang Z; Cai X
Ann Transl Med; 2022 May; 10(10):581. PubMed ID: 35722360
[TBL] [Abstract][Full Text] [Related]
77. Renin-Angiotensin-Aldosterone System and Immunomodulation: A State-of-the-Art Review.
Laghlam D; Jozwiak M; Nguyen LS
Cells; 2021 Jul; 10(7):. PubMed ID: 34359936
[TBL] [Abstract][Full Text] [Related]
78. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.
Siltari A; Murtola TJ; Talala K; Taari K; Tammela TLJ; Auvinen A
PLoS One; 2020; 15(6):e0234269. PubMed ID: 32598349
[TBL] [Abstract][Full Text] [Related]
79. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.
Pinter M; Jain RK
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978752
[TBL] [Abstract][Full Text] [Related]
80. The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).
Alashkham A; Paterson C; Windsor P; Struthers A; Rauchhaus P; Nabi G
Clin Genitourin Cancer; 2016 Oct; 14(5):398-405. PubMed ID: 27053500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
